Category Press Releases

AIDS Healthcare Foundation Pushes Gilead Sciences for Greater Patent Transparency

AIDS Healthcare Foundation Files Shareholder Proposal Urging Gilead Sciences to Increase Transparency on Patent Exclusivity Practices Access to life-saving medicines remains one of the most critical challenges in global healthcare, and for many advocates, the issue extends far beyond scientific…

Read MoreAIDS Healthcare Foundation Pushes Gilead Sciences for Greater Patent Transparency

Prothena Announces Novo Nordisk Secures FDA Fast Track Status for Coramitug (PRX004)

Prothena Reports U.S. Food and Drug Administration Grants Fast Track Status to Coramitug (PRX004) for ATTR Cardiomyopathy, Secured by Novo Nordisk Prothena Corporation plc has announced a key regulatory development for coramitug, an investigational therapy being advanced for the treatment…

Read MoreProthena Announces Novo Nordisk Secures FDA Fast Track Status for Coramitug (PRX004)

Evofem Signs Exclusive Deal to Distribute and Commercialize SOLOSEC Across Sub-Saharan Africa

Evofem Signs Exclusive Deal to Distribute and Commercialize SOLOSEC Across Sub-Saharan Africa Evofem Biosciences, Inc., a biopharmaceutical company focused on advancing innovative solutions for women’s health, has announced a strategic step to expand global access to its flagship anti-infective therapy.…

Read MoreEvofem Signs Exclusive Deal to Distribute and Commercialize SOLOSEC Across Sub-Saharan Africa

WuXi Biologics Completes Structure of Chengdu Microbial Manufacturing Facility as Key Equipment Arrives

WuXi Biologics’ Chengdu Microbial Manufacturing Facility Reaches Structural Completion with Key Equipment Installed WuXi Biologics has reached a major construction milestone in its global manufacturing expansion strategy, announcing the structural completion of its new microbial commercial manufacturing facility in Chengdu,…

Read MoreWuXi Biologics Completes Structure of Chengdu Microbial Manufacturing Facility as Key Equipment Arrives

Bristol Myers Squibb and Pfizer Partner with Mark Cuban Cost Plus Drug Company to Offer Eliquis® (apixaban)

Bristol Myers Squibb and Pfizer Partner with Mark Cuban Cost Plus Drug Company to Expand Access to Eliquis® (apixaban) The longstanding alliance between Bristol Myers Squibb and Pfizer has announced a notable expansion of its patient access strategy through a…

Read MoreBristol Myers Squibb and Pfizer Partner with Mark Cuban Cost Plus Drug Company to Offer Eliquis® (apixaban)

Anaxiom Reports Early First-in-Human Results for Novel Minimally Invasive Obesity Device, Moves Toward U.S. Feasibility Study

Anaxiom Reports Initial First-in-Human Clinical Results for Novel Minimally Invasive Obesity Device, Progresses Toward U.S. Early Feasibility Study Anaxiom Corporation, a clinical-stage innovator focused on developing minimally invasive solutions for obesity treatment, has announced the successful completion of a 12-patient…

Read MoreAnaxiom Reports Early First-in-Human Results for Novel Minimally Invasive Obesity Device, Moves Toward U.S. Feasibility Study

Late-Breaking PRESERVE Trial Data Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation

Late-Breaking PRESERVE Trial Findings Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation XVIVO, a global medical technology company specializing in organ preservation and transplantation, has announced encouraging late-breaking preliminary results from its PRESERVE Trial (NCT05881278). The study evaluates hypothermic oxygenated…

Read MoreLate-Breaking PRESERVE Trial Data Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation

Vistagen Clears FDA Review to Advance Refisolone Phase 2 for Menopause Hot Flashes

Vistagen Secures FDA “Study May Proceed” Clearance for Refisolone IND, Advancing Phase 2 Development in Menopause-Related Vasomotor Symptoms Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on advancing neuroscience through its proprietary nose-to-brain neurocircuitry platform, has announced a key…

Read MoreVistagen Clears FDA Review to Advance Refisolone Phase 2 for Menopause Hot Flashes

PureTech Reports Positive Phase 1b Data for LYT-200 in High-Risk MDS and R/R AML

PureTech Reports Positive Phase 1b Topline Data for LYT-200 in Relapsed/Refractory High-Risk MDS and AML PureTech Health plc, a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value and advancing novel therapies across a range of serious diseases, has…

Read MorePureTech Reports Positive Phase 1b Data for LYT-200 in High-Risk MDS and R/R AML